Hugel (145020.KQ) Stock Price

Hugel Price

CLOSED
180,300.00
​
Market closed

Revenue has compounded at 26.2% per year over the past 13 years to 425.11 B KRW. Earnings per share have grown at 23.4% per year over the last 13 years. Hugel's net margin stands at 33.1%, up from 23.5% several years earlier. Analysts set a median price target of 351,900.00 KRW, implying 95.2% above the current price. Of 19 analysts, 17 rate the stock a buy — an overall Buy consensus.

Hugel stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hugel business model & stock analysis

Hugel Inc is a biotechnology company based in Chuncheon, South Korea, operating in the Health Care sector. It manufactures and sells biopharmaceuticals, including botulinum toxins for treating benign essential blepharospasm and moderate to severe glabellar lines in 50, 100, and 200 unit types. The company also produces hyaluronic acid fillers for facial wrinkles under various product lines such as Chaeum Premium and Chaeum MID. Hugel Inc went public on December 24, 2015, and markets its products domestically and internationally. Its website is http://www.hugel.co.kr/

Frequently asked questions about Hugel

Analysts currently set an average price target of 353,515.00 KRW for the Hugel stock (median: 351,900.00 KRW), implying +96.1 % versus the latest price. The consensus is based on 19 analyst ratings.

19 analysts currently rate the Hugel stock: 17 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Hugel to generate revenue of 515.59 B KRW and earnings per share of 13,788.75 KRW.

Converted at the current exchange rate, the Hugel share trades at 120.34 EUR (180,300.00 KRW).

The expected revenue of Hugel is 515.59 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Hugel is 148.96 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Hugel is currently 13.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hugel stock.

The price-to-sales ratio (P/S) of Hugel is currently 3.78. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hugel stock.

The Eulerpool Quality Score for Hugel is 8/10.

The ISIN of Hugel is KR7145020004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Hugel is 145020.KQ. The ticker symbol is used to trade Hugel shares on the stock exchange.

Fair ValueTerminal
165,876.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website hugel.co.kr
Country
South Korea
Currency
KRW
Initial public offering
Dec 24, 2015
ISIN
KR7145020004
Cusip
Y3R47A100
Market capitalization
2.05 T KRWMega Cap
52-Week Range
PEG
0.80
P/E ratio
P/Ee 2026
13.79
P/Ee 2027
10.78
P/Ee 2028
8.52
P/Ee 2029
—
P/S
P/Se
3.78
EV/EBIT
10.22
P/B Ratio
2.16
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
14.82 %
Last updated Oct 19, 2026, 3:42 AM

Hugel Peer Group

Hugel FIGI

145020:KS · BBG005MWHLC5145020:KQ · BBG00BGSXG86

All fundamentals and in-depth analysis of Hugel

Our stock analysis for Hugel stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hugel. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.